摘要
目的:总结治疗中晚期非小细胞肺癌(NSCLC)中医用药规律,以期为中医中药辅助治疗提供有益参考。方法:采用回顾性资料数据分析的方法,以近10年在中国人民解放军总医院住院的非小细胞肺癌化疗患者为调查对象。提取服用中药相关信息,制定相关规则,建立数据表,计算用药频率,对结果进行分析。结果:2893人次治疗过程中共使用474味中药,用药频次排名前5位的中药依次是黄芪、白术、麦芽、茯苓、陈皮。在常用药物涉及的7类药物中,使用频次前3位的中药类分别为益气养阴、健脾和胃、活血化瘀。结论:非小细胞肺癌的治疗用药应立足于确切的病因病机辨证,体现中医整体观和辨证。非小细胞肺癌病因病机的复杂性和多样性,从而决定了其中医药治疗的多方面、多层次性。中药治疗非小细胞肺癌以补益肺脾、化痰散瘀为主。
Objective: To summarize the rules of traditional Chinese medicine for the treatment of advanced non-small cell lung cancer(NSCLC), with a view to providing useful reference for adjuvant treatment of traditional Chinese medicine. Methods: Retrospective data analysis was used to investigate the NSCLC chemotherapy patients admitted to the PLA General Hospital in the past 10 years. Extract the relevant information of taking Chinese medicine, formulate relevant rules, establish data tables, calculate the frequency of medication, and analyze the results. Extract the relevant information of taking traditional Chinese medicine, formulate relevant rules,establish data tables, calculate the frequency of drug use, and analyze the results. Results: A total of 474 traditional Chinese medicines were used in 2893 patients. The top 5 Chinese medicines were Huangqi(astragalus),Baizhu(white atractylodes), Maiya(barley sprout), Fuling(poria), Chenpi(tangerine peel). Among the seven commonly used drugs, the top 3 traditional Chinese medicine used frequently were invigorating Qi and nourishing Yin, invigorating the spleen and stomach, activating blood circulation and removing blood stasis. Conclusion: The treatment of NSCLC should be based on the exact etiology and pathogenesis differentiation, and reflect the overall view and differentiation of TCM. The complexity and diversity of the etiology and pathogenesis of NSCLC determine the multi-faceted and multi-level medical treatment. Traditional Chinese medicine treatment of NSCLC is mainly to invigorate lungs and spleen, and eliminates phlegm and remove blood stasis.
作者
李敏
窦永起
孙浩儒
王若进
李一鸣
孟帅
黄婷
LI Min;DOU Yong-qi;SUN Hao-ru;WANG Ruo-jin;LI Yi-ming;MENG Shuai;HUANG Ting(Chinese Peopled Liberation Army General Hospital,Beijing 100853,China)
出处
《中医药导报》
2020年第4期98-100,共3页
Guiding Journal of Traditional Chinese Medicine and Pharmacy
基金
中国人民解放军总医院临床科研扶持基金(2015FC-TSYS-1006)。
关键词
非小细胞肺癌
化疗
中药
用药频次
用药规律
辨证规律
non-smallcell lung cancer(NSCLC)
chemotherapy
traditional Chinese medicine
frequency of medication
rule of medication
rule of syndrome differentiation
作者简介
通讯作者:李敏,E-mail:kittenlimin1115@126.com。
